An open clinical study assessing the efficacy and safety of Factor IX Grifols®, a high-purity Factor IX concentrate, in patients with severe haemophilia B

Haemophilia

Volumn 16, Issue 2, 2010, Pages 240-246

  Lissitchkov, T ^a   Matysiak, M ^b   Zawilska, K ^c   Gercheva, L ^d   Antonov, A ^e   Montanes M ^f   Paez, A ^f  

^a National Center of Hematology   (Bulgaria)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c J Strusia Hospital   (Poland)

^d UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

^e MEDICAL UNIVERSITY PLEVEN   (Bulgaria)

^f Instituto Grifols SA Department of Clinical Trials and Pharmacovigilance   (Spain)

Author keywords

Efficacy; Factor IX; Factor IX Grifols ; Grifols; Haemophilia; Haemophilia B

Indexed keywords

BLOOD CLOTTING FACTOR 9 CONCENTRATE; GRIFOLS; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; BLEEDING; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL STUDY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG PURITY; DRUG SAFETY; HEMOPHILIA B; HEMOSTASIS; HUMAN; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SCHOOL CHILD; SUBSTITUTION THERAPY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTORS; CHILD; COAGULANTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FACTOR IX; FEMALE; HEMOPHILIA B; HEMORRHAGE; HEMOSTASIS; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); YOUNG ADULT;

EID: 77950191134     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02090.x     Document Type: Review

References (23)

1. Scharrer I. The need for highly purified products to treat hemophilia B. Acta Haematol 1995, 94:2-7.
2. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999, 95:S13-7.
3. Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992, 79:568-75.
4. Goudemand J, Peynet J, Chambost H. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. Thromb Haemost 1998, 80:919-24.
5. Schulman S, Wallensten R, White B, Smith OP. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery. Haemophilia 1999, 5:96-100.
6. Jorquera JI. Safety procedures of coagulation factors. Haemophilia 2007, 13:41-6.
7. Di Paola J. Product selection issues in the management of hemophilia B. Blood Coagul Fibrinolysis 2004, 15:S17-8.
8. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000, 26:179-88.
9. Warrier I, Lusher JM. Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coagul Fibrinolysis 1998, 9:S125-8.
10. Warrier I, Ewenstein BM, Koerper MA. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Haematol Oncol 1997, 19:23-7.
11. Thorland EC, Drost JB, Lusher JM. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999, 5:101-5.
12. Note for guidance on the clinical investigation of human plasma derived factor VIII and IX products (CPMP/BPWG/198/95 rev. 1). 2000, London, October 19th
13. Core SPC for human plasma derived and recombinant coagulation factor IX products (CPMP/BPWG/1625/99). 2000, London, June 29th
14. Cohn EJ, Strong LE, Hughes WL. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946, 68:459-75.
15. Cohn EJ, Gurd FRN, Surgenor DM. A system for the separation of the components of human blood: quantitative procedures for the separation of the protein components of human plasma. J Am Chem Soc 1950, 72:465-74.
16. Kasper CK, Aledort LM, Counts LB. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975, 34:869-72.
17. Carville DGM, Guyer KE. Coagulation testing: part 1, current methods and challenges. IVD Tech 1998, 4:59-66.
18. Ratcliff RM, Chang G, Kok T, Sloots TP. Molecular diagnosis of medical viruses. Curr Issues Mol Biol 2007, 9:87-102.
19. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 1983, 249:1743-5.
20. Shapiro AD, Di Paola J, Cohen A. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005, 105:518-25.
21. Roth DA, Kessler CM, Pasi KJ. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001, 98:3600-6.
22. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003, 9:1-23.
23. Limentani SA, Gowell KP, Deitcher SR. High-purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potential. Acta Haematol 1995, 94:12-7.